- Home
- STTK vs FNGR Comparison
STTK vs FNGR Comparison
Compare STTK & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- FNGR
- Stock Information
- Founded
- STTK 2016
- FNGR 2016
- Country
- STTK United States
- FNGR Singapore
- Employees
- STTK N/A
- FNGR N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- FNGR Computer Software: Prepackaged Software
- Sector
- STTK Health Care
- FNGR Technology
- Exchange
- STTK Nasdaq
- FNGR Nasdaq
- Market Cap
- STTK 83.8M
- FNGR 87.9M
- IPO Year
- STTK 2020
- FNGR N/A
- Fundamental
- Price
- STTK $1.92
- FNGR $1.61
- Analyst Decision
- STTK Hold
- FNGR
- Analyst Count
- STTK 6
- FNGR 0
- Target Price
- STTK $2.67
- FNGR N/A
- AVG Volume (30 Days)
- STTK 1.6M
- FNGR 204.6K
- Earning Date
- STTK 08-14-2025
- FNGR 10-14-2025
- Dividend Yield
- STTK N/A
- FNGR N/A
- EPS Growth
- STTK N/A
- FNGR N/A
- EPS
- STTK N/A
- FNGR N/A
- Revenue
- STTK $2,997,000.00
- FNGR $35,692,374.00
- Revenue This Year
- STTK N/A
- FNGR N/A
- Revenue Next Year
- STTK N/A
- FNGR N/A
- P/E Ratio
- STTK N/A
- FNGR N/A
- Revenue Growth
- STTK N/A
- FNGR 11.55
- 52 Week Low
- STTK $0.69
- FNGR $1.03
- 52 Week High
- STTK $3.95
- FNGR $5.20
- Technical
- Relative Strength Index (RSI)
- STTK 72.13
- FNGR 49.75
- Support Level
- STTK $1.68
- FNGR $1.50
- Resistance Level
- STTK $2.04
- FNGR $1.85
- Average True Range (ATR)
- STTK 0.19
- FNGR 0.12
- MACD
- STTK 0.09
- FNGR 0.02
- Stochastic Oscillator
- STTK 89.29
- FNGR 40.51
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.